Navigation Links
Shire plc: IFRS Results for the Year Ending December 31, 2007
Date:3/25/2008

llion (2006: US$nil) of which US$205.0 million (2006: US$nil) relates to capitalised in-process R&D ("IPR&D") for DYNEPO (primarily the oncology indication), as the Group considers it unlikely that it will pursue the indication for commercialisation. See Note 7 for further details.

Excluding these intangible impairment charges of US$256.4 million and the US$100.0 million charge on the effective settlement of the pre-existing relationship with New River, R&D expenditure in the year to December 31, 2007 was US$418.8 million or 19% of product sales (2006: US$295.8 million) an increase of US$123.0 million.

The increase in R&D expenditure in 2007 was due to Phase 3(b) and Phase 4 studies to support new product launches; the continuation of Phase 3 trials on velaglucerase alfa (GA-GCB); the development of the Women's Health franchise and JUVISTA; the pre-clinical development of three HGT projects and the newly in-licensed products from Amicus Therapeutics, Inc. ("Amicus") and Alba Therapeutics Corporation ("Alba").

For the year to December 31, 2007 R&D included a charge of US$16.6 million (2006: US$3.9 million) for share based compensation which included a US$4.6 million (2006: US$nil) cumulative catch up charge in respect of 2005 option awards, for further information see SG&A below.

Selling, general and administrative (SG&A) expenses

SG&A expenses increased from US$1,219.9 million (79% of product sales) in the year to December 31, 2006 to US$1,381.1 million in 2007 (64% of product sales), an increase of 13%, which is less than the product sales increase of 41%.

Year to December 31, 2007 2006 Change

US$M US$M %

_______ _______ _______

Sales costs 310.7 233.2 +33

Marketing costs 401
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
2. Shire plc: Correction Re Website
3. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
4. Shire Engages Palio
5. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
6. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
7. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
8. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
9. Shire plc: Board Changes
10. David Mott Appointed Non Executive Director at Shire
11. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Massachusetts , September 2, 2014 ... to BioData,s research and lab management services  ... management service, is pleased to announce the appointment of ... Culot most recently served as VP Marketing and Business ... life science research and clinical applications. Previously, ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 The ... and Diagnostics report provides comprehensive understanding and unprecedented ... entered into by the worlds leading life science ... and analysis of how and why companies enter ... a prospective partner’s negotiated deals terms provides critical ...
(Date:8/31/2014)... 2014 This is a professional ... the Epoxy Hardener industry in Global and ... the industry, including definitions, applications and industry chain ... analysis are provided with a focus on history, ... A comparison between the international and Chinese situation ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 The ... $5.6 billion in 2019. It is expected to ... to 2019, and was valued at $1.8 billion ... by Transparency Market Research. , For more information ... http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, titled “Companion ...
Breaking Biology Technology:Louis Culot Appointed as BioData's CEO 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 2Epoxy Hardener Industry Development Trends in Global & China Regions Now Available at ReportsnReports.com 3Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3
... Idenix Pharmaceuticals, Inc., (NASDAQ: IDIX ) announced today ... quarter of 2011 on Monday, August 8, 2011 after U.S. ... conference call at 4:30 p.m. ET on Monday, August 8, ... quarter of 2011 and provide an update on the company,s ...
... LOS ANGELES, July 21, 2011 Genesis Biopharma, Inc. ... today announced it has named retired four-star General Merrill ... served nearly four decades in the U.S. Air Force ... 1994.  The Genesis Biopharma Board now consists of 7 ...
... 2011 Sangamo BioSciences, Inc. (Nasdaq: ... use of zinc finger nucleases (ZFNs) to produce genetically modified ... of the National Academy of Sciences (PNAS) , represents a ... tissue as a source for transplant into humans.   ...
Cached Biology Technology:Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board of Directors 2Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology 2Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology 3Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology 4
(Date:8/31/2014)... A new blood test provides a fast and ... new proof-of-concept study shows. The newly developed test ... to detect active tuberculosis in children. The test ... tests in combination with speed of a blood ... for the diagnosis of tuberculosis in children, particularly ...
(Date:8/31/2014)... not busy attacking us, germs go after each other. ... disaster for the infected microbes: Sometimes viruses actually carry ... expand its diet or better attack its own hosts. ... immune system would robotically destroy anything it recognized as ... have now revealed that one variety of the bacterial ...
(Date:8/31/2014)... Over the past several decades, malaria diagnosis has changed very ... technician smears the blood across a glass slide, stains it ... the Plasmodium parasite, which causes the disease. This approach gives ... blood an important measure of disease severity but ... , A research team from the Singapore-MIT Alliance for Research ...
Breaking Biology News(10 mins):New tuberculosis blood test in children is reliable and highly specific 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 2Discovery reveals how bacteria distinguish harmful vs. helpful viruses 3A new way to diagnose malaria 2A new way to diagnose malaria 3
... such, they are relatively well studied, especially in the ... most thoroughly. First eastern US butterfly species were described ... himself, over 250 years ago. For the last ... species diversity of eastern butterflies, and every nook and ...
... A*STAR,s Institute of Molecular and Cell Biology (IMCB) have ... the pathway leading to memory and learning impairment. The ... and could be used to explain defects in the ... established knowledge could potentially facilitate exploration of strategies to ...
... plant that,s been known to drive people daffy. It,s one ... a hard-to-control weed in ponds and small lakes. But it,s ... source to produce pharmaceuticals. Now, the genome of Greater Duckweed ... as a biofuel source a big boost. In a paper ...
Cached Biology News:Two new butterfly species discovered in eastern USA 2A*STAR scientists discover protein's role in human memory and learning functions 2Pond-dwelling powerhouse's genome points to its biofuel potential 2Pond-dwelling powerhouse's genome points to its biofuel potential 3Pond-dwelling powerhouse's genome points to its biofuel potential 4
... CE 4100 high pressure pump with ... with software drive compensation, reducing pulsing to ... selectable in 0.001mL steps. , The pump ... bio-compatible., Pumps may be programmed from their ...
... filter paper sandwiches are composed of a ... of thick filter paper that are preassembled ... sandwich. These 7 x 8.5 cm membrane ... Ready Gel-sized gels and are supplied as ...
... assay kit I provides reagents and a protein ... of reducing agents and detergents. The RC DC ... includes reagents and standards sufficient for 500 standard ... RC reagent II, 250 ml alkaline copper tartrate ...
... is a state-of-the-art separation system using the ... The Eclipse integrates easily with Wyatts multi-angle ... as well as the Optilab DSP. The ... mass distributions of the particles/molecules separated by ...
Biology Products: